Tesamorelin

Tesamorelin is a synthetic analogue of endogenous Growth Hormone-Releasing Hormone (GHRH), stabilized with a trans-3-hexenoic acid modification that extends its half-life and resistance to enzymatic degradation. It is one of the few peptides to have received FDA approval, prescribed clinically for HIV-associated lipodystrophy — lending it a uniquely well-documented clinical research profile compared to most research peptides.

Tesamorelin binds to pituitary GHRH receptors, stimulating the pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, it preserves the natural feedback loop of the hypothalamic-pituitary axis, resulting in a more physiologically consistent GH elevation.

Research Areas: Visceral adipose tissue reduction · GH axis stimulation · Metabolic regulation · Cognitive function & neuroprotection · Cardiovascular risk markers · Body composition research

For research use only. Not for human consumption.